You are currently on the new version of our website. Access the old version .

46 Results Found

  • Article
  • Open Access
5 Citations
2,388 Views
20 Pages

Enhanced Anti-Melanoma Activity of Nutlin-3a Delivered via Ethosomes: Targeting p53-Mediated Apoptosis in HT144 Cells

  • Arianna Romani,
  • Giada Lodi,
  • Fabio Casciano,
  • Arianna Gonelli,
  • Paola Secchiero,
  • Giorgio Zauli,
  • Olga Bortolini,
  • Giuseppe Valacchi,
  • Daniele Ragno and
  • Rebecca Voltan
  • + 3 authors

11 October 2024

This study evaluated ethosomes as a novel nanodelivery system for nutlin-3a, a known MDM2 inhibitor and activator of the p53 pathway, to improve nutlin-3a’s poor solubility, limiting its bio-distribution and therapeutic efficacy. The potential...

  • Article
  • Open Access
11 Citations
4,012 Views
27 Pages

Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level

  • Konstantina Psatha,
  • Laxmikanth Kollipara,
  • Elias Drakos,
  • Elena Deligianni,
  • Konstantinos Brintakis,
  • Eustratios Patsouris,
  • Albert Sickmann,
  • George Z. Rassidakis and
  • Michalis Aivaliotis

31 July 2023

In most lymphomas, p53 signaling pathway is inactivated by various mechanisms independent to p53 gene mutations or deletions. In many cases, p53 function is largely regulated by alterations in the protein abundance levels by the action of E3 ubiquiti...

  • Proceeding Paper
  • Open Access
1,732 Views
4 Pages

Nutlin3a Contributes to the Cytoplasmic Retention of Androgen Receptor

  • Gulseren Ozduman,
  • Bilge Debelec Butuner and
  • Kemal Sami Korkmaz

6 December 2018

Prostate cancer cells need androgens to grow and maintain like normal prostate cells, both utilize that Androgen Receptor (AR) function. Androgen receptor (AR) is expressed throughout the prostate cancer progression plays a critical role as a transcr...

  • Article
  • Open Access
7 Citations
2,725 Views
16 Pages

Nutlin-3 Loaded Ethosomes and Transethosomes to Prevent UV-Associated Skin Damage

  • Elisabetta Esposito,
  • Francesca Ferrara,
  • Markus Drechsler,
  • Olga Bortolini,
  • Daniele Ragno,
  • Sofia Toldo,
  • Agnese Bondi,
  • Alessandra Pecorelli,
  • Rebecca Voltan and
  • Giuseppe Valacchi
  • + 2 authors

21 January 2024

The skin’s protective mechanisms, in some cases, are not able to counteract the destructive effects induced by UV radiations, resulting in dermatological diseases, as well as skin aging. Nutlin-3, a potent drug with antiproliferative activity i...

  • Article
  • Open Access
931 Views
24 Pages

Multi-Step Synthesis of Chimeric Nutlin–DCA Compounds Targeting Dual Pathways for Treatment of Cancer

  • Davide Illuminati,
  • Rebecca Foschi,
  • Paolo Marchetti,
  • Vinicio Zanirato,
  • Anna Fantinati,
  • Claudio Trapella,
  • Rebecca Voltan and
  • Virginia Cristofori

28 September 2025

Chimeric compounds represent a promising strategy in cancer therapy by simultaneously targeting multiple pathways responsible for tumour growth and survival. Their structure comprises two or more pharmacophores connected through suitable chemical lin...

  • Review
  • Open Access
25 Citations
5,938 Views
19 Pages

Human hepatocellular carcinoma (HCC) is the fifth most common cancer and is associated with poor prognosis worldwide. The molecular mechanisms underlying the pathogenesis of HCC have been an area of continuing interest, and recent studies using next...

  • Article
  • Open Access
3 Citations
1,445 Views
14 Pages

Enzymatic Desymmetrisation of Prochiral meso-1,2-Disubstituted-1,2-Diaminoethane for the Synthesis of Key Enantioenriched (−)-Nutlin-3 Precursor

  • Virginia Cristofori,
  • Davide Illuminati,
  • Chiara Bisquoli,
  • Martina Catani,
  • Greta Compagnin,
  • Giulia Turrin,
  • Claudio Trapella and
  • Anna Fantinati

10 July 2024

Herein we present the biocatalysed preparation of a mono-N-carbamate-protected precursor of antitumoral Nutlin-3a through enantioselective alkoxycarbonylation of meso-1,2-disubstituted-1,2-diaminoethane using enzyme lipases and dialkyl carbonates as...

  • Article
  • Open Access
11 Citations
4,693 Views
19 Pages

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a

  • Maria Chiara Fontana,
  • Jacopo Nanni,
  • Andrea Ghelli Luserna di Rorà,
  • Elisabetta Petracci,
  • Antonella Padella,
  • Martina Ghetti,
  • Anna Ferrari,
  • Giovanni Marconi,
  • Simona Soverini and
  • Giorgia Simonetti
  • + 9 authors

In acute myeloid leukemia (AML), the restoration of p53 activity through MDM2 inhibition proved efficacy in combinatorial therapies. WIP1, encoded from PPM1D, is a negative regulator of p53. We evaluated PPM1D expression and explored the therapeutic...

  • Article
  • Open Access
21 Citations
5,516 Views
20 Pages

MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters

  • Kester Mo Henningsen,
  • Valentina Manzini,
  • Anna Magerhans,
  • Sabrina Gerber and
  • Matthias Dobbelstein

24 December 2021

MDM2 is the principal antagonist of the tumor suppressor p53. p53 binds to its cognate DNA element within promoters and activates the transcription of adjacent genes. These target genes include MDM2. Upon induction by p53, the MDM2 protein binds and...

  • Article
  • Open Access
9 Citations
4,424 Views
25 Pages

Transcriptome Analysis of Cells Exposed to Actinomycin D and Nutlin-3a Reveals New Candidate p53-Target Genes and Indicates That CHIR-98014 Is an Important Inhibitor of p53 Activity

  • Barbara Łasut-Szyszka,
  • Beata Małachowska,
  • Agnieszka Gdowicz-Kłosok,
  • Małgorzata Krześniak,
  • Magdalena Głowala-Kosińska,
  • Artur Zajkowicz and
  • Marek Rusin

14 October 2021

Co-treatment with actinomycin D and nutlin-3a (A + N) strongly activates p53. Previously we reported that CHIR-98014 (GSK-3 kinase inhibitor), acting in cells exposed to A + N, prevents activation of TREM2-an innate immunity and p53-regulated gene as...

  • Article
  • Open Access
7 Citations
2,507 Views
14 Pages

New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics

  • Tatyana Grigoreva,
  • Aleksandra Sagaidak,
  • Daria Novikova and
  • Vyacheslav Tribulovich

The inhibition of the Mdm2-p53 protein–protein interaction is a promising strategy for anticancer therapy. However, the problem of developing secondary chemoresistance in tumors treated with such drugs has not yet been sufficiently studied. In this w...

  • Article
  • Open Access
1 Citations
2,851 Views
15 Pages

CLCA2: A Potential Guardian against Premature Senescence and Skin Aging

  • Lena Guerrero-Navarro,
  • Ines Martic,
  • Christian Ploner,
  • Pidder Jansen-Dürr and
  • Maria Cavinato

Cellular senescence, a state of irreversible growth arrest, is implicated in various age-related pathologies, including skin aging. In this study, we investigated the role of CLCA2, a calcium-activated chloride channel accessory protein, in cellular...

  • Protocol
  • Open Access
7 Citations
4,923 Views
41 Pages

Characterising Mutational Spectra of Carcinogens in the Tumour Suppressor Gene TP53 Using Human TP53 Knock-in (Hupki) Mouse Embryo Fibroblasts

  • Lisa Hölzl-Armstrong,
  • Jill E. Kucab,
  • Michael Korenjak,
  • Mirjam Luijten,
  • David H. Phillips,
  • Jiri Zavadil and
  • Volker M. Arlt

13 November 2019

DNA in dividing cells is prone to mutagenesis, with mutations making key contributions to human disease including cancer. The tumour suppressor gene TP53 is the most frequently mutated gene in human tumours. Here, we present a robust protocol for stu...

  • Article
  • Open Access
3 Citations
7,711 Views
13 Pages

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex

  • Vita M. Golubovskaya,
  • Baotran Ho,
  • Jeffrey Conroy,
  • Song Liu,
  • Dan Wang and
  • William G. Cance

21 January 2014

Focal Adhesion Kinase (FAK) is a non-receptor kinase that plays an important role in many cellular processes: adhesion, proliferation, invasion, angiogenesis, metastasis and survival. Recently, we have shown that Roslin 2 or R2 (1-benzyl-15,3,5,7-tet...

  • Article
  • Open Access
23 Citations
7,374 Views
18 Pages

20 December 2018

MAPK and p14ARF–MDM2–p53 pathways are critical in cutaneous melanomas. Here, synergistic combination of the MEK inhibitor, trametinib, with MDM2 inhibitors, nutlin-3/RG7388/HDM201, and the mechanistic basis of responses, for BRAFV600E and...

  • Article
  • Open Access
30 Citations
9,754 Views
15 Pages

MDM2 Overexpression Modulates the Angiogenesis-Related Gene Expression Profile of Prostate Cancer Cells

  • Thiagarajan Venkatesan,
  • Ali Alaseem,
  • Aiyavu Chinnaiyan,
  • Sivanesan Dhandayuthapani,
  • Thanigaivelan Kanagasabai,
  • Khalid Alhazzani,
  • Priya Dondapati,
  • Saad Alobid,
  • Umamaheswari Natarajan and
  • Appu Rathinavelu
  • + 1 author

10 May 2018

The Murine Double Minute 2 (MDM2) amplification or overexpression has been found in many tumors with high metastatic and angiogenic ability. Our experiments were designed to explore the impact of MDM2 overexpression, specifically on the levels of ang...

  • Abstract
  • Open Access
1,495 Views
1 Page

Methoxyphenyl Imidazolines as Potential Activators of p53

  • Daniil R. Bazanov,
  • Nikolay V. Pervushin,
  • Natalia A. Lozinskaya and
  • Gelina S. Kopeina

The use of p53-MDM2/X inhibitors is a prospective strategy in anti-cancer therapy for tumors with wild type p53 protein. In our study, new low-molecular-weight inhibitors of the p53-mdm2 interaction have been proposed. The two-step synthesis of the i...

  • Review
  • Open Access
2 Citations
2,418 Views
27 Pages

Antibacterial Activity of the p53 Tumor Suppressor Protein—How Strong Is the Evidence?

  • Agnieszka Gdowicz-Kłosok,
  • Małgorzata Krześniak,
  • Barbara Łasut-Szyszka,
  • Dorota Butkiewicz and
  • Marek Rusin

The p53 tumor suppressor is best known for controlling the cell cycle, apoptosis, DNA repair, and metabolism, but it also regulates immunity and is able to impede the live cycle of viruses. For this reason, these infectious agents encode proteins whi...

  • Article
  • Open Access
2 Citations
1,780 Views
16 Pages

Role of Annexin 7 (ANXA7) as a Tumor Suppressor and a Regulator of Drug Resistance in Thyroid Cancer

  • Alakesh Bera,
  • Surya Radhakrishnan,
  • Narayanan Puthillathu,
  • Madhan Subramanian,
  • Nahbuma Gana,
  • Eric Russ,
  • Harvey B. Pollard and
  • Meera Srivastava

9 December 2024

Thyroid cancer is the most common endocrine malignancy in the United States, with an overall favorable prognosis. However, some patients experience poor outcomes due to the development of resistance to conventional therapies. Genetic alterations, inc...

  • Article
  • Open Access
7 Citations
4,005 Views
12 Pages

Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

  • Joon Hee Kang,
  • Seon-Hyeong Lee,
  • Jae-Seon Lee,
  • Su-Jin Oh,
  • Ji Sun Ha,
  • Hyun-Jung Choi and
  • Soo-Youl Kim

16 June 2020

More than 50% of human cancers harbor TP53 mutations and increased expression of Mouse double minute 2 homolog (MDM2), which contribute to cancer progression and drug resistance. Renal cell carcinoma (RCC) has an unusually high incidence of wild-type...

  • Review
  • Open Access
37 Citations
10,360 Views
39 Pages

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists

  • Justyna Kocik,
  • Monika Machula,
  • Aneta Wisniewska,
  • Ewa Surmiak,
  • Tad A. Holak and
  • Lukasz Skalniak

19 July 2019

The protein p53, known as the “Guardian of the Genome”, plays an important role in maintaining DNA integrity, providing protection against cancer-promoting mutations. Dysfunction of p53 is observed in almost every cancer, with 50% of case...

  • Article
  • Open Access
16 Citations
3,824 Views
18 Pages

Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

  • Daniil R. Bazanov,
  • Nikolay V. Pervushin,
  • Egor V. Savin,
  • Michael D. Tsymliakov,
  • Anita I. Maksutova,
  • Victoria Yu. Savitskaya,
  • Sergey E. Sosonyuk,
  • Yulia A. Gracheva,
  • Michael Yu. Seliverstov and
  • Gelina S. Kopeina
  • + 1 author

The use of p53-MDM2 inhibitors is a prospective strategy in anti-cancer therapy for tumors expressing wild type p53 protein. In this study, we have applied a simple approach of two-step synthesis of imidazoline-based alkoxyaryl compounds, which are a...

  • Article
  • Open Access
10 Citations
7,336 Views
17 Pages

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53

  • Stephen L. Abrams,
  • Przemysław Duda,
  • Shaw M. Akula,
  • Linda S. Steelman,
  • Matilde L. Follo,
  • Lucio Cocco,
  • Stefano Ratti,
  • Alberto M. Martelli,
  • Giuseppe Montalto and
  • James A. McCubrey
  • + 4 authors

24 February 2022

The TP53 tumor suppressor is mutated in ~75% of pancreatic cancers. The mutant TP53 protein in pancreatic ductal adenocarcinomas (PDAC) promotes tumor growth and metastasis. Attempts have been made to develop molecules that restore at least some of t...

  • Article
  • Open Access
2 Citations
2,966 Views
12 Pages

Computational-Model-Based Biopharmaceutics for p53 Pathway Using Modern Control Techniques for Cancer Treatment

  • Amina Yasin,
  • Abdul Rehman Yasin,
  • Muhammad Rizwan Azam,
  • Ali Raza,
  • Robina Nazir and
  • Ridab Adlan Elamin Abdalla

6 June 2022

The p53 pathway has been the focus of many researchers in the last few decades owing to its pivotal role as a frontline cancer suppressant protein. It plays a vital role in maintaining cell cycle checkpoints and cell apoptosis in response to a broken...

  • Article
  • Open Access
6 Citations
5,264 Views
22 Pages

p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture

  • Aline Rangel-Pozzo,
  • Samuel Booth,
  • Pak Lok Ivan Yu,
  • Madhurendra Singh,
  • Galina Selivanova and
  • Sabine Mai

22 February 2020

The TP53 gene is a key tumor suppressor. Although the tumor suppressor p53 was one of the first to be characterized as a transcription factor, with its main function potentiated by its interaction with DNA, there are still many unresolved questions a...

  • Article
  • Open Access
7 Citations
2,430 Views
20 Pages

A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma

  • Guilherme Freimann Wermelinger,
  • Lucas Rubini,
  • Anna Carolina Carvalho da Fonseca,
  • Gabriel Ouverney,
  • Rafael P. R. F. de Oliveira,
  • Acácio S. de Souza,
  • Luana S. M. Forezi,
  • Gabriel Limaverde-Sousa,
  • Sergio Pinheiro and
  • Bruno Kaufmann Robbs

Oral squamous cell carcinoma (OSCC) represents ~90% of all oral cancers, being the eighth most common cancer in men. The overall 5-year survival rate is only 39% for metastatic cancers, and currently used chemotherapeutics can cause important side ef...

  • Article
  • Open Access
1,886 Views
17 Pages

The Strong Activation of p53 Tumor Suppressor Drives the Synthesis of the Enigmatic Isoform of DUSP13 Protein

  • Małgorzata Krześniak,
  • Barbara Łasut-Szyszka,
  • Agnieszka Będzińska,
  • Agnieszka Gdowicz-Kłosok and
  • Marek Rusin

The p53 tumor suppressor protein activates various sets of genes depending on its covalent modifications, which are controlled by the nature and intensity of cellular stress. We observed that actinomycin D and nutlin-3a (A + N) collaborate in inducin...

  • Article
  • Open Access
21 Citations
4,379 Views
18 Pages

1 September 2019

Thymic stromal lymphopoietin (TSLP) is crucial for Th2-mediated inflammation. Sepsis is a serious systemic inflammatory reaction with organ dysfunction by infection. However, the function of TSLP during sepsis is poorly understood. Thus, we investiga...

  • Article
  • Open Access
7 Citations
3,428 Views
13 Pages

Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors

  • Erika Rimondi,
  • Elisabetta Melloni,
  • Arianna Romani,
  • Veronica Tisato,
  • Fabio Casciano,
  • Gian Matteo Rigolin,
  • Daniela Milani,
  • Claudio Celeghini,
  • Giorgio Zauli and
  • Rebecca Voltan
  • + 1 author

1 July 2021

In B-chronic lymphocytic leukemia (B-CLL), the interaction between leukemic cells and the microenvironment promotes tumor cell survival. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is one of the first-in-class molecules for the treatment o...

  • Article
  • Open Access
35 Citations
6,091 Views
18 Pages

Molecular Docking and Molecular Dynamics Studies Reveal the Anticancer Potential of Medicinal-Plant-Derived Lignans as MDM2-P53 Interaction Inhibitors

  • Tagyedeen H. Shoaib,
  • Nihal Abdelmoniem,
  • Rua M. Mukhtar,
  • Amal Th. Alqhtani,
  • Abdullah L. Alalawi,
  • Razan Alawaji,
  • Mashael S. Althubyani,
  • Shaimaa G. A. Mohamed,
  • Gamal A. Mohamed and
  • Abdulrahim A. Alzain
  • + 2 authors

16 September 2023

The interaction between the tumor suppressor protein p53 and its negative regulator, the MDM2 oncogenic protein, has gained significant attention in cancer drug discovery. In this study, 120 lignans reported from Ferula sinkiangensis and Justicia&nbs...

  • Article
  • Open Access
8 Citations
3,187 Views
19 Pages

MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression

  • Yuki Murakami,
  • Kei Kimura-Masuda,
  • Tsukasa Oda,
  • Ikuko Matsumura,
  • Yuta Masuda,
  • Rei Ishihara,
  • Saki Watanabe,
  • Yuko Kuroda,
  • Tetsuhiro Kasamatsu and
  • Hiroshi Handa
  • + 5 authors

29 December 2022

MicroRNAs (miRNAs and miRs) are small (19–25 base pairs) non-coding RNAs with the ability to modulate gene expression. Previously, we showed that the miR-34 family is downregulated in multiple myeloma (MM) as the cancer progressed. In this stud...

  • Article
  • Open Access
3 Citations
3,439 Views
17 Pages

A Quantitative Systems Approach to Define Novel Effects of Tumour p53 Mutations on Binding Oncoprotein MDM2

  • Manuel Fuentes,
  • Sanjeeva Srivastava,
  • Angela M. Gronenborn and
  • Joshua LaBaer

Understanding transient protein interactions biochemically at the proteome scale remains a long-standing challenge. Current tools developed to study protein interactions in high-throughput measure stable protein complexes and provide binary readouts;...

  • Article
  • Open Access
20 Citations
5,871 Views
14 Pages

MDM2-Mediated p21 Proteasomal Degradation Promotes Fluoride Toxicity in Ameloblasts

  • Huidan Deng,
  • Atsushi Ikeda,
  • Hengmin Cui,
  • John D. Bartlett and
  • Maiko Suzuki

10 May 2019

Fluoride overexposure is an environmental health hazard and can cause enamel and skeletal fluorosis. Previously we demonstrated that fluoride increased acetylated-p53 and its downstream target p21 in ameloblast-derived LS8 cells. However, p21 functio...

  • Communication
  • Open Access
23 Citations
7,257 Views
13 Pages

Design, Synthesis and Biological Evaluation of Sulfamide and Triazole Benzodiazepines as Novel p53-MDM2 Inhibitors

  • Zhiliang Yu,
  • Chunlin Zhuang,
  • Yuelin Wu,
  • Zizhao Guo,
  • Jin Li,
  • Guoqiang Dong,
  • Jianzhong Yao,
  • Chunquan Sheng,
  • Zhenyuan Miao and
  • Wannian Zhang

5 September 2014

A series of sulfamide and triazole benzodiazepines were obtained with the principle of bioisosterism. The p53-murine double minute 2 (MDM2) inhibitory activity and in vitro antitumor activity were evaluated. Most of the novel benzodiazepines exhibite...

  • Article
  • Open Access
2 Citations
2,468 Views
25 Pages

Ezetimibe Anticancer Activity via the p53/Mdm2 Pathway

  • Charmy Twala,
  • Sibusiso Malindisa,
  • Chamone Munnik,
  • Selisha Sooklal and
  • Monde Ntwasa

Background: Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that Ezetimibe inhibits several cancers indirectly by reducing circulating...

  • Article
  • Open Access
14 Citations
4,680 Views
21 Pages

PPM1D Is a Therapeutic Target in Childhood Neural Tumors

  • Jelena Milosevic,
  • Diana Treis,
  • Susanne Fransson,
  • Gabriel Gallo-Oller,
  • Baldur Sveinbjörnsson,
  • Nina Eissler,
  • Keiji Tanino,
  • Kazuyasu Sakaguchi,
  • Tommy Martinsson and
  • John Inge Johnsen
  • + 2 authors

30 November 2021

Childhood medulloblastoma and high-risk neuroblastoma frequently present with segmental gain of chromosome 17q corresponding to aggressive tumors and poor patient prognosis. Located within the 17q-gained chromosomal segments is PPM1D at chromosome 17...

  • Article
  • Open Access
5 Citations
2,721 Views
24 Pages

Tetrasubstituted Pyrrole Derivative Mimetics of Protein–Protein Interaction Hot-Spot Residues: A Promising Class of Anticancer Agents Targeting Melanoma Cells

  • Marco Persico,
  • Paola Galatello,
  • Maria Grazia Ferraro,
  • Carlo Irace,
  • Marialuisa Piccolo,
  • Avazbek Abduvakhidov,
  • Oleh Tkachuk,
  • Maria Luisa d’Aulisio Garigliota,
  • Pietro Campiglia and
  • Caterina Fattorusso
  • + 3 authors

A new series of tetrasubstituted pyrrole derivatives (TSPs) was synthesized based on a previously developed hypothesis on their ability to mimic hydrophobic protein motifs. The resulting new TSPs were endowed with a significant toxicity against human...

  • Article
  • Open Access
22 Citations
4,336 Views
13 Pages

Chemopreventive Agent 3,3′-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells

  • Xiang Gao,
  • Jingwen Liu,
  • Kwang Bog Cho,
  • Samanthreddy Kedika and
  • Bin Guo

3,3′-Diindolylmethane (DIM) is a naturally derived chemopreventive compound. It comes from glucobrassicin, an indole glucosinolate enriched in cruciferous vegetables, and is formed in the acidic environment of the stomach after ingestion. Mouse...

  • Article
  • Open Access
902 Views
21 Pages

Development and Validation of a 7-eRNA Prognostic Signature for Lung Adenocarcinoma

  • Yiwen Sun,
  • Keng Chen,
  • Jingkai Zhang,
  • Zhijie Hu,
  • Mingmei Xiong,
  • Zhigang Fang,
  • Guanmei Chen,
  • Xiaomei Meng,
  • Baolin Liao and
  • Luping Lin
  • + 1 author

17 October 2025

Enhancer RNAs (eRNAs) are abundant in most human cells and tissues, and quantifying eRNAs has become a robust approach for biomarker discovery. While eRNAs play crucial roles in regulating biological processes and cancer progression, their functions...

  • Article
  • Open Access
3 Citations
3,940 Views
14 Pages

An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors

  • Xin Xue,
  • Gang Bao,
  • Hai-Qing Zhang,
  • Ning-Yi Zhao,
  • Yuan Sun,
  • Yue Zhang and
  • Xiao-Long Wang

1 December 2018

The judicious application of ligand or binding efficiency (LE) metrics, which quantify the molecular properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads....

  • Article
  • Open Access
1 Citations
1,327 Views
12 Pages

Latency-Associated Nuclear Antigen (LANA) Promotes Ferroptosis by Suppressing Nrf2/GPX4 and Upregulating MDM2

  • Yuejia Cao,
  • Shihan Shao,
  • Yingying Zhang,
  • Dandan Song,
  • Fei Gui,
  • Xinyi Chen,
  • Yu Hong,
  • Rong Chen,
  • Yang Song and
  • Chunhong Di
  • + 2 authors

Ferroptosis, an iron-dependent cell death driven by lipid peroxidation, is regulated by key mediators including glutathione peroxidase 4 (GPX4) and nuclear factor erythroid 2-related factor 2 (Nrf2). Kaposi’s sarcoma-associated herpesvirus (KSH...

  • Article
  • Open Access
2 Citations
2,724 Views
14 Pages

Mesenchymal Stem Cells Increase Drug Tolerance of A431 Cells Only in 3D Spheroids, Not in 2D Co-Cultures

  • Flóra Vajda,
  • Áron Szepesi,
  • Zsuzsa Erdei,
  • Edit Szabó,
  • György Várady,
  • Dániel Kiss,
  • László Héja,
  • Katalin Német,
  • Gergely Szakács and
  • András Füredi

Mesenchymal stem cells (MSCs) are an integral part of the tumor microenvironment (TME); however, their role is somewhat controversial: conflicting reports suggest that, depending on the stage of tumor development, MSCs can either support or suppress...

  • Communication
  • Open Access
3 Citations
4,112 Views
12 Pages

Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer

  • Jasmin Linh On,
  • Sahel Ghaderi,
  • Carina Rittmann,
  • Greta Hoffmann,
  • Franziska Gier,
  • Vitalij Woloschin,
  • Jia-Wey Tu,
  • Sanil Bhatia,
  • Andrea Kulik and
  • Knud Esser
  • + 4 authors

26 January 2025

Triple-negative breast cancer (TNBC) represents the most aggressive breast carcinoma subtype lacking efficient therapeutic options. A promising approach in cancer treatment is the pharmacological inhibition of murine double minute 2 (MDM2)-p53 intera...

  • Article
  • Open Access
55 Citations
8,132 Views
17 Pages

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

  • Lukasz Skalniak,
  • Justyna Kocik,
  • Justyna Polak,
  • Anna Skalniak,
  • Monika Rak,
  • Agnieszka Wolnicka-Glubisz and
  • Tad A. Holak

24 October 2018

The protein p53 protects the organism against carcinogenic events by the induction of cell cycle arrest and DNA repair program upon DNA damage. Virtually all cancers inactivate p53 either by mutations/deletions of the TP53 gene or by boosting negativ...

  • Article
  • Open Access
20 Citations
5,296 Views
16 Pages

Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects

  • Balázs Besztercei,
  • Tamás Vancsik,
  • Anett Benedek,
  • Enikő Major,
  • Mbuotidem J. Thomas,
  • Csaba A. Schvarcz,
  • Tibor Krenács,
  • Zoltán Benyó and
  • Andrea Balogh

17 August 2019

Modulated electrohyperthermia (mEHT), an innovative complementary technique of radio-, chemo-, and targeted oncotherapy modalities, can induce tumor apoptosis and contribute to a secondary immune-mediated cancer death. Here, we tested the efficiency...

  • Review
  • Open Access
6 Citations
3,648 Views
34 Pages

Transcription Factors and Methods for the Pharmacological Correction of Their Activity

  • Svetlana V. Guryanova,
  • Tatiana V. Maksimova and
  • Madina M. Azova

Transcription factors (TFs) are proteins that control gene expression by binding to specific DNA sequences and are essential for cell development, differentiation, and homeostasis. Dysregulation of TFs is implicated in numerous diseases, including ca...